Fujii Y - Search Results

1

Ozoralizumab, a Humanized Anti-TNFα NANOBODY^® Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFα IgG.

Ishiwatari-Ogata C, Kyuuma M, Ogata H, Yamakawa M, Iwata K, Ochi M, Hori M, Miyata N, Fujii Y. Ishiwatari-Ogata C, et al. Among authors: fujii y. Front Immunol. 2022 Feb 22;13:853008. doi: 10.3389/fimmu.2022.853008. eCollection 2022. Front Immunol. 2022. PMID: 35273620 Free PMC article.

2

Mitophagy reporter mouse analysis reveals increased mitophagy activity in disuse-induced muscle atrophy.

Yamashita SI, Kyuuma M, Inoue K, Hata Y, Kawada R, Yamabi M, Fujii Y, Sakagami J, Fukuda T, Furukawa K, Tsukamoto S, Kanki T. Yamashita SI, et al. Among authors: fujii y. J Cell Physiol. 2021 Nov;236(11):7612-7624. doi: 10.1002/jcp.30404. Epub 2021 May 2. J Cell Physiol. 2021. PMID: 33934360

3

A novel anti-TNF-α drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis.

Oyama S, Ebina K, Etani Y, Hirao M, Kyuuma M, Fujii Y, Iwata K, Ogawa B, Hasegawa T, Kawano S, Nakanishi Y, Okada S, Nakata K. Oyama S, et al. Among authors: fujii y. Sci Rep. 2022 Oct 27;12(1):18102. doi: 10.1038/s41598-022-23152-6. Sci Rep. 2022. PMID: 36302840 Free PMC article.

4

Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY^® compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation.

Kyuuma M, Kaku A, Mishima-Tsumagari C, Ogawa B, Endo M, Tamura Y, Ishikura KI, Mima M, Nakanishi Y, Fujii Y. Kyuuma M, et al. Among authors: fujii y. Front Immunol. 2023 Apr 14;14:1149874. doi: 10.3389/fimmu.2023.1149874. eCollection 2023. Front Immunol. 2023. PMID: 37122706 Free PMC article.

5

[Pharmacological profiles and clinical efficacy of ozoralizumab (Nanozora^® 30 ‍mg Syringes for S.C. Injection), the first Nanobody^® compound in Japan].

Kawanishi M, Fujii Y. Kawanishi M, et al. Among authors: fujii y. Nihon Yakurigaku Zasshi. 2023;158(6):490-499. doi: 10.1254/fpj.23051. Nihon Yakurigaku Zasshi. 2023. PMID: 37914330 Japanese.

6

Amelioration of collagen-induced arthritis by a novel S1P1 antagonist with immunomodulatory activities.

Fujii Y, Hirayama T, Ohtake H, Ono N, Inoue T, Sakurai T, Takayama T, Matsumoto K, Tsukahara N, Hidano S, Harima N, Nakazawa K, Igarashi Y, Goitsuka R. Fujii Y, et al. J Immunol. 2012 Jan 1;188(1):206-15. doi: 10.4049/jimmunol.1101537. Epub 2011 Nov 30. J Immunol. 2012. PMID: 22131329

7

Blocking S1P interaction with S1P₁ receptor by a novel competitive S1P₁-selective antagonist inhibits angiogenesis.

Fujii Y, Ueda Y, Ohtake H, Ono N, Takayama T, Nakazawa K, Igarashi Y, Goitsuka R. Fujii Y, et al. Biochem Biophys Res Commun. 2012 Mar 23;419(4):754-60. doi: 10.1016/j.bbrc.2012.02.096. Epub 2012 Feb 24. Biochem Biophys Res Commun. 2012. PMID: 22387544

8

Discovery of N-{5-[3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl]-4-methyl-1,3-thiazol-2-yl}acetamide (TASP0415914) as an orally potent phosphoinositide 3-kinase γ inhibitor for the treatment of inflammatory diseases.

Oka Y, Yabuuchi T, Oi T, Kuroda S, Fujii Y, Ohtake H, Inoue T, Wakahara S, Kimura K, Fujita K, Endo M, Taguchi K, Sekiguchi Y. Oka Y, et al. Among authors: fujii y. Bioorg Med Chem. 2013 Dec 15;21(24):7578-83. doi: 10.1016/j.bmc.2013.10.042. Epub 2013 Nov 7. Bioorg Med Chem. 2013. PMID: 24262886

9

Lymphopenia induced by a novel selective S1P(1) antagonist structurally unrelated to S1P.

Fujii Y, Ohtake H, Ono N, Hara T, Sakurai T, Takahashi S, Takayama T, Fukasawa Y, Shiozawa F, Tsukahara N, Hirayama T, Igarashi Y, Goitsuka R. Fujii Y, et al. Biochim Biophys Acta. 2012 Apr;1821(4):600-6. doi: 10.1016/j.bbalip.2011.12.006. Epub 2011 Dec 30. Biochim Biophys Acta. 2012. PMID: 22265714

10

Discovery and optimization of a series of 2-aminothiazole-oxazoles as potent phosphoinositide 3-kinase γ inhibitors.

Oka Y, Yabuuchi T, Fujii Y, Ohtake H, Wakahara S, Matsumoto K, Endo M, Tamura Y, Sekiguchi Y. Oka Y, et al. Among authors: fujii y. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7534-8. doi: 10.1016/j.bmcl.2012.10.028. Epub 2012 Oct 12. Bioorg Med Chem Lett. 2012. PMID: 23122859

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,435 results

Search Page